NetworkNewsWire
Editorial Coverage: The push for psychedelic medicine is
surging across North America and around the world. Scientific
evidence supports the life-changing impact this safe and natural
alternative has in treating mental illness of all types. New
research from a number of organizations, including Johns
Hopkins in Baltimore and Imperial
College in London, which revealed that patients with depressive
disorders had a clinically significant positive response to
psilocybin-assisted therapy may represent a therapeutic
breakthrough in treating multiple neurological disorders. As
research expands, so does support for the revolutionary treatment,
which has actually been around for centuries. As seen before,
anecdotal opinions often trigger scientific research which then,
with validation, drives growth in the industry as well investor
interest. That’s exactly what’s occurring in the psychedelic
therapeutics space, major upticks in both new companies entering
the space as well as investors excited about the possibilities.
Potential stakeholders in this game-changing new market are looking
for companies that can weather the complex and expensive process of
running clinical trials and bringing a drug to market. A leader in
psychedelic therapeutic research and drug development,
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF)
(Profile) has a
strong clinical pipeline with phase 2 trials underway, holds ten
provisional patents, and boasts a proven leadership and a
time-tested tradition. Other companies vying for position in the
psychedelics medicine space include COMPASS
Pathways Plc (NASDAQ: CMPS), Mind Medicine
Inc (OTCQB: MMEDF) (NEO: MMED), Numinus Wellness
Inc. (OTC: LKYSF) (NEO: NUMI) (TSX.V: NUMI) and
Field
Trip Health Ltd. (OTCQX: FTRPF) (CSE:
FTRP). Each of these companies is focused on providing
better treatments for the millions suffering from mental health
issues.
- One in four people faces a mental or neurological disorder at
some point in their lives.
- Current treatment options are inadequate, provide limited
efficacy.
- Cybin’s seasoned leadership team demonstrated prowess in
research, finance and maximizing opportunities.
- Evidenced by its recent acquisition of Adelia, Cybin is
committed to a strong, well-established IP portfolio.
Click here to view
the custom infographic of the Cybin editorial.
The Psychedelic Answers
More than 700 million
people worldwide struggle with some form of mental illness, be it
depression, addiction or post-traumatic stress disorder — and the
people counted are just those who seek help. The actual number is
likely much higher, given the high frequency of nondiagnosis as
well as stigmas and lack of effective treatments. One in four
people will face a mental or neurological disorder at some point in
their lives, yet “current treatments and the dominant model of
mental health care do not adequately
address the complex challenges of mental illness, which
accounts for roughly one-third of adult disability globally.”
More and more people are looking outside conventional protocols
for solutions, and they’re finding those solutions in the world of
psychedelic medicine, specifically psilocybins. Psilocybins are
a hallucinogenic substance found in certain types of mushroom,
dubbed magic mushrooms, and used for centuries by indigenous
cultures for religious, spiritual and health-related purposes. As
is often the case, the modern world is learning from the ancient as
mounting evidence points to these prolific fungi as a source for
long-sought-for help in mental health and neurological
disorders.
A Legacy of Success
Cybin Inc.
(NEO: CYBN) (OTCQB: CLXPF) is
intent on becoming the leader in this exciting breakthrough for
mental well-being. The company is at the forefront of the
revolution in mental health therapeutics and is developing a new
class of psychedelic medicines and treatment protocols. Driving its
commitment to excellence is the company’s impressive leadership
team of experienced professionals with a combined 80-plus years in
the pharmaceutical industry.
CEO Doug Drysdale has three decades in the health-care sector,
successfully building and turning around three pharmaceutical
companies, and co-founder Eric So has raised hundreds of millions
for various companies, directing value creation and strategic
exits. Cybin’s executive team has the experience and critical
insights to navigate through the complexities the promising
psychedelics industry offers.
Staffed with luminaries, the company’s
scientific team, helped develop widely used drugs such as
Allegra, Sabril, Anzemet and Vaniqa, and is the only scientific
team to have successfully commercialized a psychedelic drug to
date. In addition, the team has facilitated more than $2 billion in
pharmaceutical sales alongside being collectively involved in 37
exits across the biotech sector and various other verticals.
Cybin’s leadership team has a rich legacy of success and has the
proven ability to both guide the company and maximize
opportunity.
Tested, Proven Fundraising Ability
The importance of being well funded can’t be overlooked and is
especially important for research and drug development. Cybin and
its leadership team have demonstrated ability to raise funds for
key, strategic steps necessary for success. Most recently, Cybin
raised C$45 million in the largest go-public capital raise in the
Canadian psychedelic sector and a total of C$88 million across
Seed, Series-A and Series-B financing rounds.
Part of that capital was used in the company’s strategic
acquisition of
Adelia Therapeutics Inc., whose novel psychedelic molecules
allowed Cybin to diversity its portfolio and provided access to
multiple future indications. The acquisition also resulted in Cybin
obtaining a range of technologies related to novel therapeutic
delivery methods and therapeutic regimens, along with six patent
applications. The acquisition also brought with it an expanding
library of psychedelic derivative drug development candidates, with
the first lead compounds expected to enter clinical studies this
year.
A Three-Pillar Pipeline
Cybin is committed to a strong, well-established IP portfolio
and clinical pipeline, as indicated by the Adelia acquisition. The
company leads the industry in therapeutic development programs and
innovative drug delivery systems using a three-pillar strategy with
its novel drug-discovery platform, optimal novel and proprietary
drug-delivery systems, and an innovative treatment regimen.
The company’s IP model is diverse, covering chemically
synthesized molecules, delivery mechanisms, screeners, protocols
and new drug formulations alongside a merger and acquisition
strategy focused on acquiring proprietary technologies and novel
compounds and molecules. In addition, Cybin holds worldwide
exclusive rights to sublingual film delivery technology from
Intelgenx for the delivery of psilocybin and other psychedelic
molecules.
In addition, the company has key partnerships in place. Cybin
recently partnered with
neurotech pioneer Kernel to leverage its Kernel Flow, an
innovative technology designed to detect hemodynamic changes in the
brain that pulses light through the skull and into the bloodstream
to measure how much oxygen the blood is carrying at any given time.
Cybin anticipates that the quantitative measurements enabled by
Flow may improve the development, delivery and scaling of its
psychedelic therapeutics.
“Access to Kernel’s innovative Flow technology adds another
exciting dimension to the investigative work that Cybin is doing to
develop breakthrough treatments for mental health disorders such as
depression and addiction,” said CEO Doug Drysdale. “Currently,
clinical investigators rely on limited subjective information from
patients. The ability to collect quantitative data from our
sponsored drug development programs is potentially game-changing in
terms of our ability to measure where psychedelics work in the
brain in real time, and how we ultimately design our future
therapeutics. . . . This new cornerstone component of our sponsored
clinical programs follows a record-setting capital raise, listing
on the NEO Exchange and the acquisition of Adelia Therapeutics
Inc., which added significant scientific capabilities, novel
molecules, delivery mechanisms and intellectual property.”
Just this week Cybin announced that it had signed a
drug-development agreement with Catalent Inc., the leading
global provider of advanced delivery technologies, development, and
manufacturing solutions for drugs, biologics, cell and gene
therapies, and consumer health products. Cybin will be applying
Catalent’s proprietary Zydis(R) orally disintegrating tablet
technology for the delivery of its novel deuterated tryptamine, or
CYB003, a potential therapy for treatment-resistant psychiatric
disorders.
“We are excited to partner with the team at Catalent with the
aim of developing fast-acting, shorter-duration formulations of
CYB003, recently acquired as part of our acquisition of Adelia
Therapeutics,” Drysdale said. “Our focus on reducing the need for
health system resources, such as in-clinic therapist time, is an
important part of our goal to create scalable, more accessible
treatments for mental health disorders.”
There’s little doubt about the lack of effective treatments for
mental health and neurological disorders. Scientific research is
revealing a new, more effective approaches to address the massive
unmet medical need. Leaders in this new frontier of medicine will
likely be both appreciated by patients and rewarded by the
markets.
Making a Profit and a Difference
Cybin isn’t alone in the quest to make a difference in the
mental health space. Savvy companies see an opportunity in
psychedelic therapeutics and are jostling for position in an
industry destined to make a mark.
COMPASS
Pathways Plc (NASDAQ: CMPS) intends to accelerate patient
access to evidence-based innovation in mental health. “We focus
our efforts on those who are not helped by current treatments,”
states the company, which is developing its COMP360 psilocybin
therapy designed to offer relief for the millions of people who
suffer with treatment-resistant depression (TRD). The company is
pioneering the development of this therapy, in which its
proprietary formulation of synthetic psilocybin, COMP360, is
administered in conjunction with psychological support.
Mind
Medicine Inc (OTCQB: MMEDF) (NEO: MMED) is a
psychedelic medicine biotech company that discovers, develops and
deploys psychedelic-inspired medicines and therapies to address
addiction and mental illness. The company is assembling a
compelling drug development pipeline of innovative treatments based
on psychedelic substances including psilocybin, LSD, MDMA, DMT and
an Ibogaine derivative, 18-MC.
MMED is also actively pursuing the development of LSD-assisted
therapies through its Project Lucy, including a
Phase 2b trial for anxiety disorders planned to be
conducted fully through the FDA pathway.
Numinus
Wellness Inc. (OTC: LKYSF) (NEO: NUMI) (TSX.V: NUMI)
supports access to psychedelic-assisted
psychotherapy through ketamine-assisted psychotherapy and
special access and compassionate trials. Numinus partners with
practitioners in providing clients with access to
psychedelic-assisted psychotherapy, and through its recent acquisition of
Mindspace, a Quebec-based psychedelic programming leader,
Numinus now supports practitioners across three clinic
locations.
Field
Trip Health Ltd. (OTCQX: FTRPF) (CSE:
FTRP), a global leader in the development and delivery
of psychedelic therapies, recently
partnered with WHOOP, a human performance company, to measure
the biometric effects of Field Trip’s psychedelic therapies. Field
Trip is opening Field Trip Health centers across North America and
Europe for the delivery of psychedelic therapies, which have
demonstrated significant efficacy in treating mental health
conditions such as depression, anxiety and PTSD.
Surging interest in psychedelic therapeutics has sparked rising
involvement from savvy companies interested in making both a profit
and a difference as well as investors looking for the next space to
strategically make a move. Companies such as Cybin that offer the
science, the leadership and the expertise needed to succeed have a
good chance of making a real difference in the nascent
industry.
For more information about Cybin, please visit Cybin
Inc.
About NetworkNewsWire
NetworkNewsWire
(“NNW”) is a financial news and content distribution company, one
of 50+ brands within the InvestorBrandNetwork (“IBN”), that
provides: (1) access to a network of wire
solutions via InvestorWire to
reach all target markets, industries and demographics in the most
effective manner possible; (2) article and
editorial syndication to 5,000+ news outlets; (3)
enhanced press release solutions to ensure maximum
impact; (4) social media distribution via IBN
millions of social media followers; and (5) a full
array of corporate communications solutions. As a multifaceted
organization with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and
public companies that desire to reach a wide audience comprising
investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text
“STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com